ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan Sells 3,477 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan sold 3,477 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $16.94, for a total transaction of $58,900.38. Following the sale, the chief operating officer now directly owns 42,133 shares of the company’s stock, valued at approximately $713,733.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Brendan Teehan also recently made the following trade(s):

• On Monday, April 8th, Brendan Teehan sold 2,568 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $17.87, for a total transaction of $45,890.16.
• On Wednesday, March 27th, Brendan Teehan sold 5,140 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $17.90, for a total value of $92,006.00.
• On Monday, February 26th, Brendan Teehan sold 624 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $24.67, for a total value of $15,394.08.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD traded down $0.03 during trading hours on Friday, reaching $17.05. 1,159,973 shares of the stock were exchanged, compared to its average volume of 1,744,443. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -44.87 and a beta of 0.42. The stock’s fifty day simple moving average is $19.31 and its 200 day simple moving average is $23.38. ACADIA Pharmaceuticals Inc. has a 52 week low of $16.16 and a 52 week high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm had revenue of $231.04 million for the quarter, compared to analyst estimates of $223.79 million. During the same period in the prior year, the business posted ($0.26) EPS. The firm’s quarterly revenue was up 69.3% compared to the same quarter last year. Research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ACAD. Quest Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $39,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at $100,000. China Universal Asset Management Co. Ltd. increased its position in shares of ACADIA Pharmaceuticals by 97.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,202 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 2,070 shares during the period. Legato Capital Management LLC acquired a new position in ACADIA Pharmaceuticals in the fourth quarter valued at about $206,000. Finally, Old Well Partners LLC bought a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $257,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Morgan Stanley cut their target price on ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 13th. TheStreet raised shares of ACADIA Pharmaceuticals from a “d” rating to a “c” rating in a research report on Tuesday, February 27th. Oppenheimer reaffirmed a “market perform” rating and issued a $25.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, February 5th. HC Wainwright reissued a “buy” rating and set a $33.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. lowered their target price on ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, March 25th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $32.13.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.